The United States Food and Drug Administration has approved a generic version of lenacapavir, a twice-yearly injectable HIV prevention drug, allowing it to be supplied across 120 low– and middle-income countries for forty dollars a year per patient, DW reported.
Lenacapavir Injection Reduces HIV Risk by 99.9 Percent
- Mechanism of Action: Lenacapavir is a long-acting antiretroviral that acts on the HIV capsid, a structure the virus needs to function and reproduce.
- Administration Frequency: Patients receive the subcutaneous injection twice a year, offering an alternative to daily oral pre-exposure prophylaxis regimens.
- Efficacy Profile: Clinical data indicate that the biannual injection reduces the risk of acquiring HIV by 99.9 percent.
Generic Formulation Distributes at Forty Dollars Annually Across Nations
The approval follows a pricing agreement announced in September 2025 between Indian pharmaceutical manufacturer Dr. Reddy’s Laboratories, the international health purchasing initiative Unitaid, the Wits RHI health research institute in Africa, and the Clinton Health Access Initiative. Under the arrangement, the generic formulation will be distributed at forty dollars annually per patient across 120 nations. Deepak Sapra, executive director of pharmaceutical services at Dr. Reddy’s, stated that developing a complex long-acting injectable at an accessible price required solid scientific capabilities and manufacturing experience to meet an urgent access need.
Gilead Sciences originally developed the brand-name version, known as Yeztugo, which received FDA approval in June 2025. In the United States, the list price for the brand-name medication reaches approximately 28,000 dollars annually before insurance adjustments. Because of existing patent protections, the newly approved generic version cannot be sold domestically in the United States, keeping the lower-cost distribution focused on the agreed international markets designated in voluntary licensing agreements established by Gilead in late 2024.
Epidemiological Impact and Alternative Long-Acting Options
Carmen Pérez Casas, HIV lead at Unitaid, noted that missed daily doses leave individuals unprotected against transmission.
| Treatment Regimen | Administration Schedule | Reported Efficacy / Outcome | Primary Cost Benchmark |
|---|---|---|---|
| Generic Lenacapavir | Subcutaneous injection twice yearly | Reduces HIV transmission risk by 99.9% | $40 / year (120 designated countries) |
| Brand-name Yeztugo (Gilead) | Subcutaneous injection twice yearly | Prevents HIV acquisition (FDA approved 2025) | ~$28,000 / year (US list price) |
| Oral PrEP Regimens | Daily oral tablet | Protection depends on daily adherence | — |
Regulatory Approvals Across Regional Healthcare Systems
FDA approval can accelerate regulatory authorization in many other countries. In Mexico, the Federal Commission for the Protection against Sanitary Risks granted sanitary registration to lenacapavir in September 2026 following Phase 3 clinical trials that evaluated subcutaneous administration across diverse patient populations. With that registration, Mexico joined countries and regions that have authorized this preventive alternative, including the United States, Brazil, and European Union member states, while the World Health Organization issued recommendations in July 2025 to incorporate long-acting agents for HIV prevention.
Philippe Duneton, executive director of Unitaid, highlighted that early risk assumption by international health agencies shortens the timeline between scientific discovery and actual clinical availability in resource-limited settings. International health organizations emphasize that turning this regulatory milestone into reduced infection rates now depends on sustained public health financing and distribution logistics.
Patients Must Consult a Physician Before Starting Treatment
Lenacapavir is used for pre-exposure prophylaxis under medical supervision; it does not protect against other sexually transmitted infections and should form part of an integrated sexual health strategy. Patients should consult a qualified physician for medical evaluation and follow-up before initiating any antiretroviral regimen.
Future Implementation and Access Milestones
With the FDA’s approval of the generic formulation, international health organizations face the complex task of procuring and transporting the medication to the populations that need it most.
References
- Gistand, N. Long-acting lenacapavir and cabotegravir and viral suppression among people with HIV. JAMA Network Open, 9(10). doi:10.1001/jamanetworkopen.2026.38182
- World Health Organization (WHO). (2025). Recommendations to incorporate long-acting agents for HIV prevention.
- U.S. Food and Drug Administration (FDA). Regulatory announcements and generic drug review documentation for antiretroviral therapies.
Always consult a licensed healthcare provider regarding clinical decisions and prevention protocols.
